Vicore Pharma postpones publication of year-end report

Mölndal, February 13, 2019 - Vicore Pharma Holding AB (publ) has decided to postpone the publication of the year-end report for 2018. The year-end report will be published on March 15, 2019, instead of previously announced February 22, 2019.

The reason for postponing the report is the decision to convert the company’s accounting principles to IFRS as per the year-end report for 2018. Conversion to IFRS is an important part of the preparations for the up-listing to the Stockholm Nasdaq main list which is planned to take place during the second half of 2019.

For further information, please contact:

Hans Jeppsson, CFO: +46 70 553 14 65, hans.jeppsson@vicorepharma.com 

About Vicore Pharma Holding AB (publ)
Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”). As a result of the acquisition of INIM Pharma AB in August 2018, the company’s pipeline was expanded with a second drug development program, VP02. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on IPF with regards to both the underlying disease and the severe cough associated to IPF. VP01 and VP02 are also evaluated for other indications within the area of interstitial lung diseases. The acquisition of INIM Pharma meant an expansion of Vicore Pharma's operations and that the company's strategy became focused on developing drugs for the treatment of rare and severe lung diseases.

VP01 will initiate an expanded dose escalating Phase I study in the beginning of 2019 and the Phase IIa study in IPF patients is expected to start six months later. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020.

The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm. The company´s certified adviser is Erik Penser Bank, telephone: +46 8 463 83 00, e-mail: certifiedadviser@penser.se. For more information, see: www.vicorepharma.com

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com